What is the Market's View on Phathom Pharmaceuticals Inc (PHAT) Stock's Price and Volume Trends Tuesday?

Overall market sentiment has been high on Phathom Pharmaceuticals Inc (PHAT) stock lately. PHAT receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Phathom Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PHAT!

See Full PHAT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With PHAT Stock Today?

Phathom Pharmaceuticals Inc (PHAT) stock is lower by -3.42% while the S&P 500 is higher by 0.07% as of 11:23 AM on Tuesday, Aug 22. PHAT is lower by -$0.52 from the previous closing price of $15.04 on volume of 46,404 shares. Over the past year the S&P 500 has risen 6.40% while PHAT is higher by 44.15%. PHAT lost -$4.39 per share in the over the last 12 months. To screen for more stocks like Phathom Pharmaceuticals Inc click here.

More About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Click Here to get the full Stock Report for Phathom Pharmaceuticals Inc stock.